Equities researchers at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
NASDAQ EVOK opened at $5.25 on Thursday. The stock has a 50-day simple moving average of $4.80 and a two-hundred day simple moving average of $5.72. The firm has a market capitalization of $45.13 million, a P/E ratio of -2.87 and a beta of 0.38. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $17.88.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The business had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- Canadian Penny Stocks: Can They Make You Rich?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What Investors Need to Know to Beat the Market
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
